Eupraxia Pharmaceuticals (NASDAQ:EPRX) Upgraded at Wall Street Zen
Wall Street Zen raised shares of Eupraxia Pharmaceuticals to a "hold" rating in a report on Saturday...
MarketBeat·5d ago
More News
FY2025 Earnings Forecast for EPRX Issued By HC Wainwright
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Free Report) - Research analysts at HC Wainwright boosted their FY2025 earnings estimates for Eupraxia Pharmaceuticals in a note issued to investors on...
MarketBeat·5d ago
Wall Street Analysts Think Eupraxia Pharmaceuticals Inc. (EPRX) Could Surge 75.08%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 75.1% in Eupraxia Pharmaceuticals Inc. (EPRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·6d ago
Is Elanco Animal Health (ELAN) Stock Outpacing Its Medical Peers This Year?
Here is how Elanco Animal Health Incorporated (ELAN) and Eupraxia Pharmaceuticals Inc. (EPRX) have performed compared to their sector so far this year.
Zacks·29d ago
Eupraxia Pharmaceuticals Inc. (EPRX) is a Great Momentum Stock: Should You Buy?
Does Eupraxia Pharmaceuticals Inc. (EPRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·1mo ago
Eupraxia Pharmaceuticals Inc. (EPRX) Upgraded to Buy: Here's Why
Eupraxia Pharmaceuticals Inc. (EPRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·1mo ago
Wall Street Analysts Believe Eupraxia Pharmaceuticals Inc. (EPRX) Could Rally 85.12%: Here's is How to Trade
The consensus price target hints at an 85.1% upside potential for Eupraxia Pharmaceuticals Inc. (EPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·1mo ago
Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE...
PR Newswire·9mo ago
Eupraxia Pharmaceuticals Announces CFO Succession
Eupraxia Pharmaceuticals Announces CFO Succession Eupraxia Pharmaceuticals Announces CFO Succession PR Newswire VICTORIA, BC, Feb. 18, 2025 - Bruce Cousins is retiring, and former CFO Alex Rothwell...
PR Newswire·9mo ago
Eupraxia's DiffuSphere Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months
Eupraxia's DiffuSphere Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months Eupraxia's DiffuSphere Technology Demonstrates Targeted...